Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162


Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.

Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB; Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators and Coordinators.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):409-18. doi: 10.1161/CIRCOUTCOMES.113.000139. Epub 2013 Jul 9.


Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up.

Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP, Feldman T, Stahle E, Escaned J, Banning AP, Gunn JP, Colombo A, Steyerberg EW, Mohr FW, Serruys PW.

Circulation. 2015 Apr 7;131(14):1269-77. doi: 10.1161/CIRCULATIONAHA.114.013042. Epub 2015 Feb 24.


Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).

Sedlis SP, Jurkovitz CT, Hartigan PM, Kolm P, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, Boden WE, Weintraub WS; COURAGE Study Investigators.

Am J Cardiol. 2013 Dec 1;112(11):1703-8. doi: 10.1016/j.amjcard.2013.07.034. Epub 2013 Sep 3.


Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).

Bradley SM, Chan PS, Hartigan PM, Nallamothu BK, Weintraub WS, Sedlis SP, Dada M, Maron DJ, Kostuk WJ, Berman DS, Teo KK, Mancini GB, Boden WE, Spertus JA.

Am J Cardiol. 2015 Jul 15;116(2):167-73. doi: 10.1016/j.amjcard.2015.03.057. Epub 2015 Apr 17.


Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.

Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.


The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.

Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):172-82. doi: 10.1161/CIRCOUTCOMES.110.940502. Epub 2011 Feb 8.


Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.

Maron DJ, Spertus JA, Mancini GB, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE; COURAGE Trial Research Group.

Am J Cardiol. 2009 Oct 15;104(8):1055-62. doi: 10.1016/j.amjcard.2009.05.056. Epub 2009 Aug 28.


Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia.

Mancini GB, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE.

JACC Cardiovasc Interv. 2014 Feb;7(2):195-201. doi: 10.1016/j.jcin.2013.10.017. Epub 2014 Jan 15.


Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators.

Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.


Interpreting the results of the COURAGE trial: a non-interventionalist perspective.

Boden WE.

Rev Cardiovasc Med. 2009;10 Suppl 2:S34-44. Review.


Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction.

Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O'Connor CM, Sastry A, Shaw LJ, Borges-Neto S.

JACC Cardiovasc Imaging. 2012 Jul;5(7):715-24. doi: 10.1016/j.jcmg.2012.01.019.


Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial).

Padala SK, Sidhu MS, Hartigan PM, Maron DJ, Teo KK, Spertus JA, Mancini GB, Sedlis SP, Chaitman BR, Heller GV, Weintraub WS, Boden WE.

Am J Cardiol. 2015 Nov 15;116(10):1509-15. doi: 10.1016/j.amjcard.2015.08.012. Epub 2015 Aug 31.


Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.

Acharjee S, Teo KK, Jacobs AK, Hartigan PM, Barn K, Gosselin G, Tanguay JF, Maron DJ, Kostuk WJ, Chaitman BR, Mancini GB, Spertus JA, Dada MR, Bates ER, Booth DC, Weintraub WS, O'Rourke RA, Boden WE; COURAGE Trial Research Group.

Am Heart J. 2016 Mar;173:108-17. doi: 10.1016/j.ahj.2015.07.020. Epub 2015 Jul 26.


Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.

Fernandez SF, Boden WE.

Curr Atheroscler Rep. 2010 Nov;12(6):423-31. doi: 10.1007/s11883-010-0135-2. Review.


Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.

Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, Escarcega RO, Lipinski MJ, Baker NC, Kitabata H, Ota H, Suddath WO, Satler LF, Pichard AD, Waksman R.

Circ Cardiovasc Interv. 2014 Dec;7(6):768-76. doi: 10.1161/CIRCINTERVENTIONS.114.001341. Epub 2014 Dec 2.


Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.

Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA.

JAMA. 2011 May 11;305(18):1882-9. doi: 10.1001/jama.2011.601. Erratum in: JAMA. 2011 Jun 15;305(23):2418.


Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons.

Arnold SV, Magnuson EA, Wang K, Serruys PW, Kappetein AP, Mohr FW, Cohen DJ; SYNTAX Investigators.

Circ Cardiovasc Qual Outcomes. 2012 May;5(3):267-75. doi: 10.1161/CIRCOUTCOMES.111.964585. Epub 2012 Apr 10.


Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.

Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM.

Circulation. 2016 Jan 5;133(1):39-47. doi: 10.1161/CIRCULATIONAHA.115.019768. Epub 2015 Nov 10.


The truth and consequences of the COURAGE trial.

Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, Stone GW.

J Am Coll Cardiol. 2007 Oct 16;50(16):1598-603. Epub 2007 Sep 17.

Supplemental Content

Support Center